PORCINE ADENOVIRUSES (PAdV)
LEVELS: Highly unlikely: No controls necessary; Highly unlikely: No evidence of non-foodborne zoonotic transmission; Highly effective: Routine on-farm biosecurity measures are effective in preventing farm-to-farm transmission; Easy: Distinct clinical signs and/or existing test(s) available at local/regional laboratory(s); Negligible: No measurable losses; Negligible: Little or no market disruption when disease occurs on one or more farms; Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments; Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy; No availability: Effective treatments not currently available in the US (or have not been developed); No availability: Effective vaccines not currently available in the US (or have not been developed); Not feasible: Eradication extremely unlikely
OVERVIEW
Porcine adenoviruses (PAdVs) are non-enveloped DNA viruses in the family Adenoviridae, genus Mastadenovirus, that cause generally subclinical to mild infections in swine. Five serotypes have been identified: PAdV-1 through PAdV-5, belonging to three species (Mastadenovirus porcusterium, porcusquartum, and porcusquintum). PAdVs have been isolated from pigs with diarrhea, encephalitis, nephritis, respiratory disease, and aborted fetuses, as well as from clinically healthy pigs. Infections generally manifest as subclinical to mild, exhibiting low to moderate pathogenicity and rarely causing diseases of economic consequence in swine herds. The most common clinical presentation is gastroenteritis in pigs 1-4 weeks of age, characterized by mild diarrhea, dehydration, anorexia, and reduced weight gain, but mortalities are rare. PAdVs are transmitted via the fecal-oral route and aerosol exposure, with shedding continuing for up to 14 weeks post-weaning. The viruses are relatively stable in the environment, resisting inactivation at room temperature for up to 10 days, but are readily inactivated by bleach, formaldehyde, alcohol, and phenolic compounds. Most adult swine are seropositive, and maternal antibodies appear to moderate infection in young piglets. Due to the mild nature of infections, there is little incentive to develop vaccines, and control relies on good biosecurity and sanitation practices.
FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No controls necessary
The chapter explicitly states that "PAdVs are not known to have public health significance." Swine are the only known natural host species susceptible to PAdV. While swine can be experimentally infected with human adenovirus, there is no evidence of reverse transmission from pigs to humans. Human adenovirus type 5 has been used as a vaccine vector for swine diseases, but this represents artificial use of the human virus, not zoonotic transmission of porcine adenoviruses. No foodborne transmission risk exists.
NON-FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No evidence of non-foodborne zoonotic transmission
PAdVs are host-specific and do not infect humans through any route. The chapter states that "PAdV is not contagious to humans." While humans have their own adenoviruses, the porcine adenoviruses are distinct and lack the ability to infect human cells or cause human disease. Occupational exposure to infected pigs poses no zoonotic risk.
EFFECTIVENESS OF ON-FARM BIOSECURITY IN PREVENTING FARM-TO-FARM TRANSMISSION
Level: Highly effective: Routine on-farm biosecurity measures are effective in preventing farm-to-farm transmission
PAdV transmission can be controlled through standard biosecurity: (1) Transmission routes: "Most PAdVs are transmitted via fecal–oral route or aerosol exposure"; urine may also be a source based on virus isolation from kidneys; (2) Environmental stability: "PAdVs are relatively stable, resisting inactivation at room temperature for up to 10 days"—this allows fomite transmission via "boots, clothing, bedding, transport vehicles, feed utensils, and perhaps feed"; (3) Susceptibility to disinfection: Viruses are "readily inactivated by bleach, formaldehyde, alcohol, and phenolic compounds"; (4) No vectors: "Vectors are not known to be involved in the transmission of PAdV." Standard biosecurity practices including sanitation, disinfection, and preventing introduction of infected animals can effectively control PAdV transmission.
DIFFICULTY OF DETECTING AND CONFIRMING INFECTION
Level: Easy: Distinct clinical signs and/or existing test(s) available at local/regional laboratory(s)
Multiple well-established diagnostic methods are available: (1) Electron microscopy: Virions can be detected in fecal and intestinal fluids by transmission EM; (2) Histopathology: Intranuclear basophilic Cowdry type A inclusion bodies in enterocytes are characteristic; (3) Immunodetection: IF staining on frozen sections and IHC staining detect PAdV antigens rapidly; (4) Virus isolation: "PAdV can be readily isolated in cell culture from fecal samples, intestinal contents, or homogenates of lung or kidney" using PK-15 cells or primary porcine kidney cells; CPE appears 2-5 days post-inoculation with characteristic "grape-like" clusters; (5) PCR: PCR and real-time qPCR assays detect PAdV in feces and can differentiate serotypes; (6) Serology: Virus neutralization assays and IFA tests diagnose infection. The chapter recommends that definitive diagnosis should be confirmed by IF, IHC, or virus isolation rather than histology alone.
FINANCIAL IMPACT ON FARM'S COST OF PRODUCTION
Level: Negligible: No measurable losses
PAdV infections have minimal economic impact: (1) Subclinical predominance: "PAdV infections generally manifest as subclinical to mild, exhibiting low to moderate pathogenicity and rarely causing diseases of economic consequence in swine herds"; (2) Mild clinical signs: When clinical, signs include "mild dehydration, anorexia, and reduced weight gain, but mortalities are rare"; (3) Age-limited disease: Most common in pigs 1-4 weeks of age; "PAdVs are most frequently detected in weaned pigs and rarely in adult animals"; (4) Self-limiting: Disease resolves without intervention; (5) Rare severe forms: Neurological, respiratory, reproductive, and disseminated infections "have also been reported" but are uncommon. The chapter notes the "mild nature of PAdV infections" as the reason vaccines have not been developed.
EFFECT ON DOMESTIC OR EXPORT MARKETS
Level: Negligible: Little or no market disruption when disease occurs on one or more farms
PAdV detection has no trade or market implications: (1) Not reportable: PAdV is not a WOAH-listed or notifiable disease; (2) Endemic globally: Found in pig populations worldwide with high seroprevalence in adults (23-83% depending on study and region); (3) Subclinical predominance: Most infections do not produce recognizable disease; (4) No public health concern: Not zoonotic. Detection of PAdV does not affect herd status, animal movements, or export certification.
PATHOGEN'S ABILITY TO DEVELOP AND SPREAD RESISTANCE
Level: Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments
PAdV is a DNA virus (family Adenoviridae) that does not carry, acquire, or transmit antimicrobial resistance genes. The virus poses no AMR concerns. Five serotypes exist with genetic diversity, but this represents natural viral variation rather than antimicrobial resistance.
AMR DEVELOPMENT DRIVEN BY DISEASE MANAGEMENT
Level: Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy
No antiviral treatments exist for PAdV. The mild, self-limiting nature of infections means treatment is rarely needed. The chapter makes no mention of antimicrobial treatment for PAdV infections. Secondary bacterial infections could theoretically require treatment, but given the typically mild clinical presentation with rare mortality, antimicrobial use associated with PAdV management would be minimal.
AVAILABILITY OF EFFECTIVE TREATMENT OPTIONS
Level: No availability: Effective treatments not currently available in the US (or have not been developed)
No specific antiviral treatments exist for PAdV infection. The chapter does not discuss treatment because the disease is self-limiting and rarely requires intervention. Management is supportive if needed. Pigs recover through their own immune response.
AVAILABILITY OF EFFECTIVE VACCINES OR BACTERINS
Level: No availability: Effective vaccines not currently available in the US (or have not been developed)
The chapter explicitly states: "Due to the mild nature of PAdV infections, there is little incentive to produce vaccines." No commercial vaccines exist for PAdV in swine. Prevention relies on "good biosecurity and sanitation to reduce environmental fecal contamination." Maternal antibodies from seropositive sows provide passive protection to piglets, as "the frequency of PAdV shedding increases in conventional piglets after weaning as colostrum-derived antibody concentrations decline."
FEASIBILITY OF ERADICATING THE DISEASE FROM THE US
Level: Not feasible: Eradication extremely unlikely
PAdV eradication is not feasible and not warranted: (1) High prevalence: Seroprevalence rates of 15-83% reported in various surveys; high detection rates in fecal samples (up to 71% of pooled samples in some studies); (2) Environmental stability: Survives up to 10 days at room temperature; detected in swine facility wash water; (3) Prolonged shedding: Pigs may shed virus for up to 14 weeks post-weaning; virus detected in tissues up to 48 days post-infection; (4) Subclinical infections: Widespread subclinical infection makes identification and elimination impractical; (5) Low economic impact: The minimal disease significance means eradication would not be cost-justified. The practical approach is control through biosecurity rather than eradication.